A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS

Health Technology Assessment

Volumn 6, Issue 26, 2002, Pages

  Sandercock, P ^a   Berge, E ^a   Dennis, M ^a   Forbes, J ^a   Hand, P ^a   Kwan, J ^a   Lewis, S ^a   Lindley, R ^a   Neilson, A ^a   Thomas, B ^a   Wardlaw, J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 3,3 BIS(3 FLUOROPHENYL) N METHYLPROPYLAMINE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 METHYLGLUTAMIC ACID; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ACETYLSALICYLIC ACID; ALTEPLASE; AMPA RECEPTOR ANTAGONIST; ANTIOXIDANT; APTIGANEL; AR R 15896; BMS 204532; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; CORTICOSTEROID DERIVATIVE; DIZOCILPINE; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; FIBRINOLYTIC AGENT; GAVESTINEL; GROWTH FACTOR; HEPARIN; KAINIC ACID RECEPTOR ANTAGONIST; LUMBROKINASE; METHYLXANTHINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; OPIATE ANTAGONIST; PIRACETAM; POTASSIUM CHANNEL STIMULATING AGENT; REPINOTAN; SARUPLASE; SCAVENGER; SEROTONIN AGONIST; SIPATRIGINE; SODIUM CHANNEL BLOCKING AGENT; STREPTOKINASE; TIRILAZAD; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; VINPOCETINE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID;

AMBULANCE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL OBSERVATION; CLINICAL PATHWAY; CLINICAL PRACTICE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DETERIORATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EDUCATION PROGRAM; EMERGENCY TREATMENT; EVIDENCE BASED MEDICINE; FAMILY; FIBRINOLYTIC THERAPY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HEALTH PROMOTION; HUMAN; HYPERGLYCEMIA; INDUCED HYPOTHERMIA; INFECTION; MEDICAL EDUCATION; META ANALYSIS; MORTALITY; NATIONAL HEALTH SERVICE; NEUROPROTECTION; NONHUMAN; OUTCOMES RESEARCH; PATIENT ATTITUDE; PHLEBITIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; STATISTICAL ANALYSIS; STROKE; SURVIVAL; UNITED KINGDOM; UNITED STATES;

EID: 0036434644     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta6260     Document Type: Review

References (238)

1. Sudlow CLM, Warlow CP, International Stroke Incidence Studies Collaboration. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. Stroke 1997;28:491-9.
2. Rothwell P.M. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 2001;357:1612-16.
3. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston: Harvard University Press; 1996.
4. MacDonald BK, Cockrell OC, Sander JWAS, Shorvon SV. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2001;123(665):676.
5. Wolfe CD. The impact of stroke. Br Med Bull 2000;56:275-86.
6. The Stroke Association. Stroke care: reducing the burden of disease. London: The Stroke Association; 1998.
7. Evers M, Goosens M, Ament A, Maarse J. Economic evaluation in stroke research. Cerebrovasc Dis 2001;11:82-91.
8. British Heart Foundation. Coronary heart disease statistics: British Heart Foundation Statistics. London: British Heart Foundation; 1998.
9. Grieve R, Hutton J, Bhalla A, Rastenye D, Ryglewicz D, Wolfe CD, on behalf of the Biomed II European Study of Stroke Care. A comparison of the costs and survival of hospital admitted stroke patients across Europe. Stroke 2001;32:1684-91.
10. Holloway R, Benesch C, Rahilly C, Courtright C, Abad-Santos F. A systematic review of cost-effectiveness research of stroke evaluation and treatment. Stroke 1999;30:1340-9.
11. Fagan S, Morgenstern L, Pettita A, Ward R, Tilley B, Marler J, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883-90.
12. Stegmayr B, Asplund K. Exploring the declining case-fatality in acute stroke. Population-based observations in the northern Sweden MONICA project. J Intern Med 1996;240:143-9.
13. Bonita R. Epidemiology of stroke. Lancet 1992;339(342):344-8.
14. Menken M, Munsat TL, Toole JF. The Global Burden of Disease Study. Implications for neurology. Arch Neurol 2000;57:418-20.
15. Gubitz G, Sandercock PAG, Counsell C. Antiplatelet therapy for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
16. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
17. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581-7.
18. Jørgensen HS, Nakayama H, Kammersgaard LP, Raaschou O, Olsen TS. Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model. BMJ 1999;319:288-9.
19. Katzan L, Furlan AJ, Lloyd L, Frank J, Harper D, Hinchey J, et al. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland area experience. JAMA 2000;283:1151-8.
20. Johnston S, Fung L, Gillum L, Smith W, Brass L, Lichman J, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic centers. The influence of ethnicity. Stroke 2001;32:1061-8.
21. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JJ. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001;32:1832-40.
22. Koennecke H-C, Nohr R, Leistner S, Marx P. Intravenous Rt-PA for Ischemic stroke. Team performance over time, safety and efficacy in a single-center, 2 year experience. Stroke 2001;32:1074-8.
23. Adams HP, Brott TG, Furlan AJ. Guidelines for thrombolytic therapy in stroke: A supplement to the guidelines for the management of patients with acute ischaemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1996;27:1711-18.
24. Handschu R, Garling A, Heuschmann P, Kolominsky-Rabas P, Ergbuth F, Neundorfer B. Acute stroke management in the general hospital. Stroke 2001;32:866-70.
25. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
26. Hallan S, Asberg A, Indredavik B, Wideroe TE. A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke. J Intern Med 1999;246:549-59.
27. Chambers M, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value in Health 2002;5(2):82-97.
28. Dewey H. Cost of acute stroke: Is rt-PA cost-effective? Presented at Sixth International Symposium on Stroke and Thrombolytic Therapy. Hamilton Island, Australia 2000.
29. European Ad Hoc Consensus Group. European strategies for early intervention in stroke. Cerebrovasc Dis 1996;6(315):324.
30. Hoffman JR. Tissue plasminogen activator for acute ischemic stroke: Is the CAEP position statement too negative? Can J Emerg Med 2001;3:183-5.
31. Wade DT, Intercollegiate Working Party for Stroke. National clinical guidelines for stroke (available on-line at: www.rcplondon.ac.uk). London: The Royal College of Physicians of London; 2000.
32. Canadian Association of Emergency Physicians Committee on Thrombolytic Therapy for acute Ischaemic Stroke. Thrombolytic therapy for acute ischemic stroke. Can J Emerg Med 2001;3:8-12.
33. Torgerson D, Campbell M. Cost effectiveness calculations and sample size. BMJ 2000;321:697.
34. Samsa G, Reutter R, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscombe J, et al. Performing cost-effectiveness analysis by integrating randomised trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke. J Clin Epidemiol 1999;52:259-71.
35. Peto R, Collins R, Gray R. Large-scale randomised evidence: Large simple trials and overviews of trials. J Clin Epidemiol 1995;48(1)23-40.
36. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber S, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556-85.
37. Ketley D, Woods K.L. Impact of clinical trials on clinical practice: Example of thrombolysis for acute myocardial infarction. Lancet 1993;342:891-4.
38. Bogousslavsky J, Brott T, Diener HC, Estol C, Fieschi C, Grotta JC, et al. Optimising intensive care in stroke: A European perspective. Cerebrovasc Dis 1997;7:113-28.
39. Consensus committee. Consensus statement - Stroke treatment and service delivery. J R Coll Physicians Edinb 2001;31Suppl. 8:2-3.
40. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
41. Bhalla A, Rudd AG. Therapeutic advances in acute ischaemic stroke. Int J Clin Pract 1999;53(4):295-300.
42. Bhalla A, Wolfe CD, Rudd AG. Management of acute physiological parameters after stroke. QJ Med 2001;94:167-72.
43. Langhorne P, Fraser P, Shields M, MacIntosh G, Stott D. Evaluation of an acute care protocol for stroke patients: A controlled clinical trial. Cerebrovasc Dis 2001;11 Suppl 11:35.
44. Langhorne P. How should hospital care be organised? J R Coll Physicians of Edinb 2001;31 Suppl 8:29-32.
45. Langhorne P, Tong B, Stott D. Association between physiological homeostasis and early recovery after stroke. Stroke 2001;31:2526-7.
46. Cavallini A, Micieli G, Zambrelli E, Quaglini S, Rognoni C. Role of continuous physiological monitoring in acute phase of stroke. Cerebrovasc Dis 2001;11 Suppl 4:117.
47. Indredavik B, Bakke F, Slordahl S, Rokseth R, Haheim L. Treatment in a combined acute and rehabilitation unit. Which aspects are most important? Stroke 2001;30:917-23.
48. Sinha S, Warburton L. The evolution of stroke units - Towards a more intensive approach? Q J Med 2000;93:633-8.
49. Wolfe CD, Rudd AG, Dennis MS, Warlow C, Langhorne P. Taking stroke care seriously. In the absence of evidence we should manage acute stroke as an emergency. BMJ 2001;323:5-6.
50. Department of Health. Stroke. National service framework for older people. London: Department of Health; 2001. p. 1-61.
51. Asplund K, Rajakangas A-M, Kuulasmaa K, Thorvaldsen P, Bonita R, Stegmayr B, et al. Multinational comparison of diagnostic procedures and management of acute stroke: The WHO MONICA study. Cerebrovasc Dis 1996;6:66-74.
52. Caro J, Huybrechts KF, Duchesne I, for the Stroke Economic Analysis Group. Management patterns and costs of acute ischemic stroke: An international study. Stroke 2000;31(3)582-90.
53. Weir NU, Sandercock PAG, Lewis SC, Signorini D, Warlow CP, on behalf of the IST Collaborative Group. Variations between countries in outcome after stroke in the International Stroke Trial (IST). Stroke 2001;32:1370-7.
54. Weir NU, Dennis MS, on behalf of the Scottish Outcomes Group. Towards a national system for monitoring the quality of hospital-based stroke services. Stroke 2001;32:1415-21.
55. Rudd AG, Irwin P, Pearson M. National audit of stroke improves quality of care. Cerebrovasc Dis 2001;11 Suppl 4:14.
56. Rudd AG, Irwin P, Lowe D, Pearson M. Ageism and sexism in the delivery of stroke care. Cerebrovasc Dis 2001;11 Suppl 4:14.
57. Baron JC, Von Kummer R, Del Zoppo G. Treatment of acute ischaemic stroke: Challenging the concept of a rigid time window. Stroke 1995;26:2219-21.
58. Marler J, Tilley B, Brott T, Lyden P, Grotta JC, Broderick J, et al. Early stroke treatment associated with better outcome. The NINDS rt-PA stroke study. Neurology 2001;55:1649-55.
59. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
60. Wardlaw JM, Warlow CP. Thrombolysis in acute ischaemic stroke - does it work? Stroke 1992;23:1826-39.
61. Haley EC, Jr., Brott TG, Sheppard GL, Barsan W, Broderick J, Marler J, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993;24:1000-4.
62. Morris AD, Ritchie C, Grosset DG, Adams FG, Lees KR. A pilot study of streptokinase for acute cerebral infarction. Q J Med 1995;88:727-31.
63. Hacke W, Kaste M, Fieschi C, Danilo T, Lesaffre E, Von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274(13):1017-25.
64. Clark WM, Wissoman S, Hamandas JH, Albers GW, Madden KP, Hamilton S, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. JAMA 1999;282:2019-26.
65. Ohtomo E, Araki G, Itoh E, Tohgi H, Matsuda T, Atarashi J. Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Multi-center double-blind study in comparison with placebo. Clinical Evaluation/Rinsho Hyoka 1985;13:711-51.
66. Atarashi J, Ohtomo E, Araki G, Itoh E, Tohgi H, Matsuda T. Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis - multi-center double blind study in comparison with placebo. Clinical Evaluation/Rinsho Hyoka 1985;13:659-709.
67. Abe T, Kazama M, Naito J, Ueda M, Tanaka T, Higuchi H, et al. Clinical evaluation for efficacy of tissue cultured urokinase (tcuk) on cerebral thrombosis by means of multi-centre double blind study. Blood and Vessel (Japan) 1981;12:321-41.
68. Multicentre Acute Stroke Trial Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-14.
69. Albers GW, Clark WM, Madden KP, Hamilton SA. The ATLANTIS T-PA Acute Stroke Trial: results for patients treated within 3 hours of stroke onset. Stroke 2000;31(1):307.
70. Donnan GA, Davis SM, Chambers B, Gates P, Hankey G, McNeil J, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-6.
71. Hacke W, Kaste M, Fieschi C, Von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
72. Multicenter Acute Stroke Trial (MASTE-E) Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
73. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976-82.
74. Yamaguchi T, Hayakawa T, Kiuchi H, Thrombolysis Study Group. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993;3:269-72.
75. Del Zoppo G, Higashida R, Furlan AJ, Pessin M, Rowley HA, Gent M, et al. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11.
76. Furlan AJ, Higashida R, Wechsler LR, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. JAMA 1999;282:2003-11.
77. NINDS rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109-18.
78. Kwiatkowski T, Libman RB, Frankel M, Tilley B, Morgenstern L, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781-7.
79. Hacke W. The results of the European Cooperative Stroke Study II (ECASS II), a placebo-controlled, randomized study of thrombolytic therapy. Eur J Neurol 1998;5 Suppl 3:S9.
80. Ciccone A, Motto C, Aritzu E, Piana A, Candelise L, on behalf of the MAST-I Group. Negative interaction of aspirin and streptokinase in acute ischemic stroke: Further analysis of the Multicenter Acute Stroke Trial - Italy. Cerebrovasc Dis 2000;10:61-4.
81. Cornu C, Boutitie F, on behalf of the TAS-PP Group. Thrombolysis in Acute Stroke Pooling Project: a meta-analysis on individual patient data. J Clin Neurosci 1999;6(1):20-3.
82. Cornu C, Boutitie F, Candelise L, Boissel JP, Donnan GA, Hommel M, et al. Streptokinase in acute ischemic stroke: An individual patient data meta-analysis. The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000;31:1555-60.
83. Touzani O, Young AR, MacKenzie ET. The window of therapeutic opportunity following focal cerebral ischaemia. In: Krieglstein J, Oberpichler-Schwenk H, editors. Pharmacology of Cerebral Ischaemia. Stuttgart: Medpharm; 1994. p. 575-88.
84. The European Ad Hoc Consensus Group. Neuroprotection as initial therapy in acute stroke. Third report of an ad hoc consensus group meeting. Cerebrovasc Dis 1998;8:59-72.
85. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-13.
86. Dorman PJ, Sandercock PAG. Considerations in the design of clinical trials of neuroprotective therapy in stroke. Stroke 1996;27:1507-15.
87. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-8.
88. Samsa G, Matchar D. Have randomised trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 2001;32:669-74.
89. Gorelick P. Neuroprotection in acute ischaemic stroke: A tale of for whom the bell tolls? Lancet 2000;355:1925-6.
90. Tirilazad International Steering Committee. Tirilazad mesylate in acute ischemic stroke: A systematic review. Stroke 2000;31(9):2257-65.
91. Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke (protocol for a Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
92. Alderson P, Roberts I. Corticosteroids for acute traumatic brain injury (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
93. Yates D, Roberts I. Corticosteroids in head injury. It's time for a large simple randomised trial. BMJ 2000;321:128-9.
94. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
95. Ricci S, Celani MG, Cantisani TA, Righeti E. Piracetam in acute stroke: a systematic review. J Neurol 2000;247(4):263-6.
96. Ricci S, Celani MG, Righetti E, Cantisani AT. Piracetam for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
97. Greener J, Whurr R, Enderby P. Pharmacological treatment for aphasia following stroke (protocol for a Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
98. Bath PM, Bath FJ, Asplund K. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
99. Bereczki D, Fekete I. Vinpocetine for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
100. Corbett D, Thornhill J. Temperature modulation (hypothermic and hyperthermic conditions) and its influence on histological and behavioral outcomes following cerebral ischemia. Brain Pathol 2000;10(1):145-52.
101. Correia M, Silva M, Veloso M. Cooling therapy for acute stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
102. Alderson P, Signorini D. Therapeutic hypothermia for head injury (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
103. Huh PW, Belayev L, Zhao W, Koch S, Busto R, Ginsberg MD. Comparative neuroprotective efficacy of prolonged moderate intraischemic and postischemic hypothermia in focal cerebral ischemia. J Neurosurg 2000;92(1):91-9.
104. Kammersgaard LP, Rasmussen BH, Jorgensen HS, Reith J, Weber U, Olsen TS. Feasibility and safety of inducing modest hypothermia in awake patients with acute stroke through surface cooling: a case-control study: the Copenhagen Stroke Study. Stroke (Online) 2000;31(9):2251-6.
105. Candelise L, Ciccone A. Gangliosides for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
106. Bath FJ, Bath PM, Butterworth RJ. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
107. Correia M, Veloso M, Correia C. Antioxidants for acute stroke (protocol for a Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
108. Saver JL, Wilterdink J. Choline precursors for acute and subacute ischemic and hemorrhagic stroke (protocol for a Cochrane Review). In: The Cochrane Library. Issue 3. In: The Cochrane Library. 2001.
109. Muir KW, Lees KR. Excitatory amino acid modulators for acute ischaemic stroke (protocol for a Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
110. Gandolfo C, Sandercock P, Conti M. Lubeluzole for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2002.
111. Camarata PJ, Heros RC, Latchaw RE. 'Brain attack': The rationale for treating stroke as a medical emergency. Neurosurgery 1994;34(1):144-57.
112. Morris DL, Rosamond W, Madden K, Schultz C, Hamilton S. Prehospital and emergency department delays after acute stroke: The Genentech Stroke Presentation Survey. Stroke 2000;31(11):2585-90.
113. Sacks H, Chalmers TC, Smith JRH. Randomized versus historical controls for clinical trials. Am J Med 1982;72:233-40.
114. Chalmers TC, Celano P, Sacks H, Smith H. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309:1358-61.
115. The Cochrane Stroke Group. In: The Cochrane Library. Issue 3. Oxford: Update Software; 2000.
116. The Cochrane Controlled Trials Register (Centra/CCTR). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2000.
117. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Factors delaying hospital admission in acute stroke. The Copenhagen Stroke Study. Neurology 1996;47:383-7.
118. Tilley BC, Lyden P, Brott TG, Lu M, Levine SR, Welch KMA. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischaemic stroke. Arch Neurol 1997;54:1466-74.
119. Feldmann E, Gorgon N, Brooks JM, Brass LM, Fayad PB, Sawaya KL et al. Factors associated with early presentation of acute stroke. Stroke 1993;24:1805-10.
120. Lacy CR, Suh DC, Bueno M, Kostis JB. Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (STROKE). Stroke 2001;32(1):63-9.
121. Gomez CR, Malkoff MD, Sauer CM, Tulyapronchote R, Burch CM, Banet GA. Code stroke. An attempt to shorten inhospital therapeutic delays. Stroke 1994;25(10):1920-3.
122. Wester P, Radberg J, Lundgren B, Peltonen M. Factors associated with delayed admission to hospital and in-hospital delays in acute stroke and TIA: A prospective, multicenter study. Stroke 1999;30(1):40-8.
123. Streifler JY, Davidovitch S, Sendovski U. Factors associated with the time of presentation of acute stroke patients in an Israeli community hospital. Neuroepidemiology 1998;17(3):161-6.
124. Siu YC, Wong TW, Lau CC. Candidates for thrombolytic treatment in acute ischaemic stroke - where are our patients in Hong Kong? J Accid Emerg Med 1999;16(6):412-7.
125. Collins DR, O'Neill D, McCormack PME. Potential for treatment with thrombolysis in an Irish stroke unit. Ir Med J 1999;92(1):236-8.
126. Ferro JM, Melo TP, Oliveira V, Crespo M, Canhao P, Pinto AN. An analysis of the admission delay of acute strokes. Cerebrovasc Dis 1994;4:72-5.
127. Rasmussen BH, Germer U, Olsen TS. Acute stroke: Dial 112 or call your 'GP'? Eur J Neurol 2000;7 Suppl 3:110.
128. Fiorelli M, Falcou A, Sacchetti ML, Toni D, Di Angelantonio E, Ferrari M, et al. The Rome emergency departments network for acute stroke: pilot study on incidence, referral pathways, and eligibility for thrombolytic therapy in Rome urban area. Ital J Neurol Sci 1999;20 4 Suppl:S137.
129. Ravindrane A, Croft-Baker J, Jarrett D, Severs MP. Causes of delay in hospital assessment after stroke. Age Ageing 2000;29 Suppl 2:57.
130. Grond M, Stenzel C, Schumulling S, Rudolf J, Neveling M, Lechleuthner A, et al. Early intravenous thrombolysis for acute ischaemic stroke in a community-based approach. Stroke 1998;29:1544-9.
131. Liu M, Fisher M, Yuan G, Zheng H. Early presentation of acute stroke in a Chinese population. Cerebrovasc Dis 1995;5:362-5.
132. Lin CS, Tsai J, Woo P, Chang H. Prehospital delay and emergency department management of ischemic stroke patients in Taiwan, R.O.C. Prehosp Emerg Care 1999;3:194-200.
133. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999;33(1):9-14.
134. Yoneda Y, Tabuchi M, Ohsumi Y, Yoshida T, Ohkawa S, Uehara T, et al. Pre- and in-hospital emergency systems for acute ischaemic stroke in a Japanese hospital. J Stroke Cerebrovasc Dis 2000;9(2):297-8.
135. Fogelholm R, Murros K, Rissanen A, Ilmavirta M. Factors delaying hospital admission after acute stroke. Stroke 1996;27(3):398-400.
136. Anderson NE, Broad JB, Bonita R. Delays in hospital admission and investigation in acute stroke. BMJ 1995;311(6998):162.
137. Herderschee D, Limburg M, Hijdra A, Bollen A. Pluvier J, te Water W. Timing of hospital admission in a prospective series of stroke patients. Cerebrovasc Dis 1991;1:165-7.
138. Pistollato G, Ermani M. Time of hospital presentation after stroke. A multicenter study in north-east Italy. Ital J Neurol Sci 1996;17:401-7.
139. Englander RN, Morich DH, Minniti MM. Accelerating the evaluation of acute stroke patients in a community hospital. Neurology 1998;50:A114.
140. Alberts MJ, Perry A, Dawson DV, Bertels C. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke 1992;23:352-6.
141. Smith WS, Corry M, Fazackerley J, Isaacs M. Improved paramedic sensitivity in identifying stroke victims in the prehospital setting. Prehosp Emerg Care 1999;3:207-10.
142. Kidwell CS, Saver JL, Schubert GB, Eckstein M, Starkman S. Design and retrospective analysis of the Los Angeles Prehospital Stroke Screen (LAPSS). Prehosp Emerg Care 1998;2(4):267-73.
143. Barsan WG, Brott TG, Broderick JP, Haley EC, Jr., Levy DE, Marler JR. Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients. Stroke 1994;25(11):2132-7.
144. Harbison J, Massey A, Barnett L, Hodge D, Ford GA. Rapid ambulance protocol for acute stroke. Lancet 1999;353(9168):1935.
145. Kothari R, Barsan W, Brott T, Broderick J. Ashbrock S. Frequency and accuracy of prehospital diagnosis of acute stroke. Stroke 195;26(6):937-941.
146. Bartolini M, Ceravolo MG, Polonara S, Polonara G, Reginelli R, Provinciali L. Thrombolysis in ischemic stroke: evaluation of operative difficulties. Arch Gerontol Geriatr 1995;20:49-54.
147. Panayiotou BN, Fotherby MD, Potter JF, Castleden CM. Eligibility of acute stroke patients for pharmacological therapy. Age Ageing 1994;23:384-7.
148. Williams LS, Bruno A, Rouch D, Marriott DJ. Stroke patients' knowledge of stroke. Influence on time of presentation. Stroke 1997;28:912-5.
149. Andre C, Moraes-Neto BM, Novis SAP. Experience with t-PA treatment in a large south American city. J Stroke Cerebrovasc Dis 1998;7(4):255-8
150. Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB, Bratina P, et al. Intravenous tissue plasminogen activator for acute ischaemic stroke. Feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.
151. Bornstein N, Karepov VG. A call for improvement in prehospital stroke identification. Stroke 2000;31:309.
152. Wein TH, Staub L, Felberg R, Hickenbottom SL, Chan W, Grotta JC, et al. Activation of emergency medical services for acute stroke in a nonurban population: the T.L.L. Temple Foundation Stroke Project. Stroke 2000;31(8):1925-8.
153. Rosamond WD, Gorton RA, Hinn AR, Hohenhaus SM, Morris DL. Rapid response to stroke symptoms: the Delay in Accessing Stroke Healthcare (DASH) Study. Acad Emerg Med 1998;5:45-51
154. Bratina P, Greenberg L, Pasteur W, Grotta JC. Current emergency department management of stroke in Houston, Texas. Stroke 1995;26:409-14.
155. Lannehoa Y, Bouget J, Pinel JF, Garnier N, Leblanc JP, Branger B. Analysis of time management in stroke patients in three French emergency departments from stroke onset to computed tomography scan. Eur J Emerg Med 1999;6:95-103.
156. Casetta I, Granieri E, Gilli G, Laura G, Tola MR, Paolino E. Temporal trend and factors associated with delayed hospital admission of stroke patients. Neuroepidemiology 1999;18:255-64.
157. Mayer-Reichenauer M, Dachenhausen A, Bosak P, Funk G, Schwarz S, Aichinger-Steiner M. et al. Prospective study of factors delaying admission to a stroke unit: the need for public education and training programmes for emergency physicians and paramedics. Cerebrovasc Dis 1998;8 Suppl 4:35.
158. Morris DL, Rosamond W, Hinn AR, Gorton RA. Time delays in accessing stroke care in the emergency department. Acad Emerg Med 1999;6:218-23.
159. Hodgson S. Emergency management of acute ischaemic stroke in Canadian hospitals. Can Med Assoc J 1998;159 6 Suppl:S15-S18.
160. Kothari R, Jauch E, Broderick J, Brott T, Sauerbeck L, Khoury J, et al. Acute stroke: delays to presentation and emergency department evaluation. Ann Emerg Med 1999;33(1):3-8.
161. Charleston AJ, Barber PA, Bennett P, Spriggs DA, Harris RG, Anderson NE. Management of stroke in Auckland Hospital in 1996. N Z Med J 1999;112(1083):71-4.
162. Salisbury HR, Banks BJ, Footitt DR, Winner SJ, Reynolds DJM. Delay in presentation of patients with acute stroke to hospital in Oxford. Q J Med 1998;91:635-40.
163. Smith MA, Doliszny KM, Shahar E, McGovern PG, Arnett DK, Luepker RV. Delayed hospital arrival for acute stroke: The Minnesota Stroke Survey. Ann Intern Med 1998;129:190-6.
164. Harper GD, Haigh RA, Potter JF, Castleden CM. Factors delaying hospital admission after stroke in Leicestershire. Stroke 1992;23(6):835-8.
165. Alberts MJ, Bertels C, Dawson DV. An analysis of time of presentation after stroke. JAMA 1990;263(1):65-8.
166. Azzimondi G, Bassein L, Fiorani L, Nonino F, Montaguti U, Celin D, et al. Variables associated with hospital arrival time after stroke. Effect of delay on the clinical efficiency of early treatment. Stroke 1997;28:537-42.
167. Biller J, Patrick JT, Shepard A, Adams HP. Delay time between onset of ischemic stroke and hospital arrival. J Stroke Cerebrovasc Dis 1993;3(4):228-30.
168. Kay R, Woo J, Poon WS. Hospital arrival time after onset of stroke. J Neurol Neurosurg Psychiatr 1992;55:973-4.
169. Wang XD, Guo H, Zhang XY, Zhu H, Li YH, Zhou G. An observation on the time of hospital arrival and correct diagnosis with CT in acute cerebral stroke patients. Cerebrovasc Dis 1997;7:89-93.
170. Becker K, Fruin M, Gooding T, Tirschwell D, Love P, Mankowski T. Community-based education improves stroke knowledge. Cerebrovasc Dis 2001;11(1):34-43.
171. Schroeder EB, Rosamond WD, Morris DL,Evenson KR, Hinn AR. Determinants of use of emergency medical services in a population with stroke symptoms: The second Delay in Accessing Stroke Healthcare (DASH II) Study. Stroke 2000;31(11):2591-6.
172. Duncan PW, Harrison DJ, Lai SM, Cook SF, Rymer MM. Factors affecting elapsed time between acute stroke and presentation. Stroke 2000;31:308.
173. Menon SC, Pandey DK, Morgenstern LB. Critical factors determining access to acute stroke care. Neurology Neurology 1998;51:427-32.
174. Johnston F, Wardlaw JM, Dennis MS, Lewis S, Nimmo G, Lindley R, et al. Delays in stroke referrals. Lancet 1999;354:47-8.
175. Engelstein E, Margulies J, Jeret JS. Lack of t-PA use for acute ischaemic stroke in a community hospital: High incidence of exclusion criteria. Am J Emerg Med 2000;18:257-60.
176. Malik MM, Gomez CR, Tulyapronchote R, Malkoff MD, Bandlamudi R,Banet GA. Delay between emergency room arrival and stroke consultation. J Stroke Cerebrovasc Dis 1993;3(3):177-80.
177. Ebrahim S. Redfern J. Stroke care - A matter of chance: A national survey of stroke services. 1999.
178. Lindley R, Amayo EO, Marshall J, Sandercock PA, Dennis MS, Warlow CP. Acute stroke treatment in UK hospitals: The Stroke Association survey of consultant opinion. J R Coll Physicians Lond 1995;29(6):479-84.
179. Villar-Cordova C, Morgensternn LB, Barnholtz JS, Frankowski RF, Grotta JC. Neurologists' attitudes regarding rt-PA for acute ischemic stroke. Neurology 1998;50(5):1491-4.
180. Zweifler R.M, Brody ML, Graves GC,U TT, Drinkard R, Cunningham S, et al. Intravenous t-PA for acute ischaemic stroke: Therapeutic yield of a code stroke system. Neurology 1998;50:501-3.
181. Evenson KR, Rosamond W, Morris DL. Prehospital and in-hospital delays in acute stroke care. Neuroepidemiology 2001;20:65-76.
182. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999;281(12):1112-20.
183. Weltermann BM, Rogalewski A, Homann J, Berger K, Schulte H, Assmann G, et al. Knowledge about stroke among the German population. Dtsch Med Wochenschr 2000;125(14):416-20.
184. Kaste M, Skyhoj OT, Orgogozo J, Bogousslavsky J, Hacke W. Organization of stroke care: Education, stroke units and rehabilitation. European Stroke Initiative (EUSI). Cerebrovasc Dis 2000;10 Suppl 3:1-11.
185. National Stroke Association consensus panel. Stroke: The first six hours. Emergency evaluation and treatment. NSA consensus statement. J Stroke Cerebrovasc Dis 1993;3:133-43.
186. Wellwood I, Dennis MS, Warlow CP. Perceptions and knowledge of stroke among surviving patients with stroke and their carers. Age Ageing 1994;23(4):293-8.
187. Pancioli AM, Broderick J, Kothari R, Brott T, Tuchfarber A, Miller R, et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA 1998;279(16):1288-92.
188. Rodgers H, Bonds S, Curless R. Inadequacies in the provision of information to stroke patients and their families. Age Ageing 2001;30:129-33.
189. Grilli R, Freemantle N, Minozzi S, Domenighetti G, Finer D. Mass media interventions: effects on health services utilisation (Cochrane Review). The Cochrary Library. Issue 2. Oxford: Update Software; 2001.
190. Barsan WG, Brott TG, Broderick JP, Haley EC, Levy DE, Marler JR. Time of hospital presentation in patients with acute stroke. Arch Intern Med 1993;153(22):2558-61.
191. Howe CA. Current provision of care for older persons in A & E units in the UK. Accid Emerg Nurs 1998;6(4):211-18.
192. Ebrahim S, Harwood R. Stroke. Epidemiology, evidence, and clinical practice. 2nd edition. Oxford: Oxford University Press; 1999.
193. Ferro JM. Is hospital admission urgent in stroke? Rev Neurol 1997;25(143):1110-12.
194. Barnaby W. Stroke intervention. Emerg Med Clin North Am 1990:8(2):267-80.
195. Kaste M. Thrombolysis in ischaemic stroke - present and future: role of combined therapy. Cerebrovasc Dis 2001;11 Suppl 1:55-9.
196. National Institute of Neurological Disorders and Stroke. Proceedings of a
197. Wallis LA, Guly HR. Improving care in accident and emergency departments. BMJ 2001;323(7303):39-42.
198. Brainin M, Bornstein N, Boysen G, Demarin V. Acute neurological stroke care in Europe: results of the European Stroke Care Inventory. Eur J Neurol 2000;7(1):5-10.
199. Wardlaw JM, Lewis SC, Sandercock PA, Ricci S, Spizzichino L. Why do Italian stroke patients receive CT scans earlier than UK patients? International Stroke Trial Collaborators in Italy and the UK. Postgrad Med J 1999;75(879):18-21.
200. Beauchamp NJ, Jr., Barker PB, Wang PY, vanZijl PC. Imaging of acute cerebral ischemia. Radiology 1999:212(2):307-24.
201. Schroeder SA, Myers LP, McPhee SJ, Showstack JA, Simborg DW, Chapman SA, et al. The failure of physician education as a cost containment strategy. Report of a prospective controlled trial at a university hospital. JAMA 1984;252(2):225-30.
202. Goodpastor WA, Montoya ID. Motivating physician behaviour change: social influence versus financial contingencies. Int J Health Care Qual Assurance 1996;9(6):4-9.
203. Steffensen FH, Olesen F, Sorensen HT. Implementation of guidelines on stroke prevention. Fam Pract 1995;12(3):269-73.
204. Royal College of Physicians. National Clinical Guidelines for Stroke. London: Royal College of Physicians; 2001.
205. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342:1317-22.
206. Kidd D, Stout RW. The assessment of acute stroke in general medical wards. Disabil Rehabil 1996;18(4):205-8.
207. Davenport RJ, Dennis MS, Warlow C. Improving the recording of the clinical assessment of stroke patients using a clerking pro forma. Age Ageing 1995;24:43-8.
208. Forbes JF, Isard P. The cost of stroke to the National Health Service in Scotland. Cerebrovasc Dis 1992;2:47-50.
209. Forbes JF, Dennis MS. Costs and health outcomes of stroke patients. Final Project Report submitted to the Health Service and Public Health Research Committee. Edinburgh: Chief Scientist Office, Scottish Home and Health Department; 1995.
210. Chen ZM, Sandercock PAG, Pan HC, Counsell C, Collins R, Liu LS, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240-9.
211. Wardlaw JM, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
212. Dorman P, Dennis MS, Sandercock. Are the modified 'simple questions' a valid and reliable measure of health related quality of life after stroke? J Neurol Neurosurg Psychiatry 2000;69:487-93.
213. Post PN, Stiggelbout A, Wakker P. Utility of health states after stroke. A systematic review of the literature. Stroke 2001;32:1425-9.
214. Wardlaw JM, Lewis S, Dennis MS, Counsell C, McDowall M. Is visible infarction on computed tomography associated with an adverse prognosis in acute ischaemic stroke? Stroke 1998;29:1315-19.
215. National Health Service in Scotland, Information and Stastistics Division, Common Services Agency, Edinburgh. Scottish Health Service Costs. Year Ended 31st March 1999. Edinburgh: 1999.
216. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth community stroke study. Stroke 2000;31:2080-6.
217. Scottish Health Service Costs 1998-99 for Western General Hospital, Edinburgh. 1999.
218. British National Formulary (BNF40); September 2000.
219. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Pharmacoeconomics 1999;16 (5(2)):577-93.
220. Chambers M. The MEDTAP model (abstract). Cerebrovasc Dis 1998;8 Suppl 4:50.
221. Sonnenberg FA, Beck JR. Markov models in medical decision making; a practical guide. Med Decis Making 1993;13:322-8.
222. Ballesey J, Sheldon AM. Healthcare applications of decision analytic modelling. Health Economics in Prevention and Care 2000;1:37-43.
223. Milne R, Nuitjen M, Weinstein M, Zhou X. Decision analytic modelling in the evaluation of health technologies: a consensus statement. Pharmacoeconomics 2000;12:443-4.
224. Rowat AM, Wardlaw JM, Dennis MS, Warlow C. Does feeding alter arterial oxygen saturation in patients with acute stroke? Stroke 2000;31:2134-40.
225. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19(5):604-7.
226. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospital cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626-34.
227. Section E1.3: Mortality: Age- and sex-specific death rates for 1998. In: Scottish Health Statistics, editor. National Statistics, ISD Scotland, 2000. Edinburgh: 2000.
228. Chartered Institute of Public Finance and Accountancy (CIPFA). Health Database 1995. Volume 3A Provider Database. Activity Costs Analysis CIPFA London: CIPFA, 1995.
229. Netten A, Dennett J. Unit Costs of Health and Social Care 1996. Kent: Personal Social Services Research Unit, University of Kent; 1996.
230. Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: A new approach. BMJ 2001;322:1596-8.
231. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999;19:635-8.
232. Vermeer F, Simoons ML, de Zwan C. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Br Heart J 1988;59:527-34.
233. Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. Eur Heart J 1991;12:694-9.
234. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3(2).
235. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ 1993;306:570-2.
236. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156(16):1829-36.
237. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke 1994;25(9):1721-5.
238. Caro J, Huybrechts C. Stroke treatment evaluation model (STEM). Predicting long-term costs from functional status. Stroke 1999;30:2574-9.